The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Self-administered Topical 5% Imiquimod Cream for External Anogenital Warts
Abstract
OBJECTIVE: To compare the safety and effectiveness of 5% and 1% imiquimod cream with vehicle cream in the treatment of external anogenital warts. DESIGN: Randomized, double-blind, placebo-controlled comparison that evaluated patients for total clearance of their warts. Patients who experienced total clearance were evaluated for recurrence in a 12-week follow-up. SETTING: Eleven ambulatory offices, including both private physician offices and referral medical centers. PATIENTS: Three hundred eleven healthy men and women aged 18 years or older with 2 to 50 external anogenital warts were recruited from the practices of investigators, referring physicians, and advertisements. Eighty-two additional patients were screened but did not qualify. Four patients discontinued use of the medication because of adverse effects. INTERVENTIONS: Five percent imiquimod (Aldara) cream, 1% imiquimod cream, or vehicle cream was applied to all external warts overnight 3 times each week for 16 weeks, or until all treated warts disappeared, whichever occurred first. MAIN OUTCOME MEASUREMENTS: The number of patients experiencing the elimination of all baseline warts and the recurrence rate of these warts. In addition, the reduction in baseline wart area the duration of therapy required to eliminate warts, and the frequency and severity of adverse reactions were principal measurements. RESULTS: In the intent-to-treat analysis, 54 (50%) of 109 patients who received 5% imiquimod cream, 21 (21%) of 102 of those who received 1% imiquimod cream, and 11 (11%) of 100 patients treated with vehicle cream experienced eradication of all treated baseline warts. The difference between the effectiveness of 5% imiquimod cream and the vehicle cream was statistically significant (P < .001). Of those patients whose warts cleared during therapy, 13% of patients who received 5% imiquimod experienced a recurrence of at least 1 wart. Recurrences occurred in none of the patients who used 1% imiquimod cream and in 10% of patients who used the vehicle cream. Local erythema was the most common adverse reaction, but the majority of patients in each group experienced no or only mild local inflammatory reactions. There were no differences in incidences of flulike symptoms among treatment groups. CONCLUSIONS: Five percent imiquimod cream is an effective and safe self-administered therapy for external anogenital warts when applied 3 times a week overnight for up to 16 weeks. The recurrence rate is low.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EPIDEMIOLOGY OF GENITAL HUMAN PAPILLOMAVIRUS INFECTION
KOUTSKY, L. A., GALLOWAY, D. A., & HOLMES, K. K. (1988) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036020 · Cited by 711
19. Department of Internal Medicine
(1999) · Sheep's Song · doi:10.1525/9780520923393-021 · Cited by 646
Interferon Therapy for Condylomata Acuminata
Eron, L. J., Fn, J., Tucker, S., Prawer, S. E., MILLS, J. S., Murphy, K., Hickey, M., Rogers, M., Flannigan, S., Hien, N. T., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610233151704 · Cited by 294
Cytokine induction by the immunomodulators imiquimod and S-27609
Testerman, T. L., Gerster, J. F., Imbertson, L. M., Reiter, M. J., Miller, R. L., Gibson, S. J., Wagner, T. L., & Tomai, M. A. (1995) · Journal of Leukocyte Biology · doi:10.1002/jlb.58.3.365 · Cited by 265
Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine.
Sidky, Y. A., Borden, E. C., Weeks, C. E., et al. (1992) · PubMed · Cited by 169
Cytokine induction in mice by the immunomodulator imiquimod
Reiter, M. J., Tester man, T. L., Miller, R. L., Weeks, C. E., & Tomai, M. A. (1994) · Journal of Leukocyte Biology · doi:10.1002/jlb.55.2.234 · Cited by 168
Harrison, C. J., Jenski, L. J., Voychehovski, T., & Bernstein, D. I. (1988) · Antiviral Research · doi:10.1016/0166-3542(88)90032-0 · Cited by 154
Megyeri, K., Au, W.-C., ROSZTÓCZY, I., Raj, N. B. K., Miller, R. L., Tomai, M. A., & Pitha, P. M. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.4.2207 · Cited by 139
Treatment of Genital Condylomata with Topical 5-Fluorouracil
Krebs, H. B. (1991) · Dermatologic Clinics · doi:10.1016/s0733-8635(18)30420-0 · Cited by 29
Cited by
The epidemiology of human papillomavirus infections
Baseman, J. G., & Koutsky, L. A. (2005) · Journal of Clinical Virology · doi:10.1016/j.jcv.2004.12.008 · Cited by 955
Toll‐like receptors control autophagy
Delgado, M. A., Elmaoued, R. A., Davis, A. S., Kyei, G., & Deretic, V. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.31 · Cited by 744
Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease
Lacey, C. J. N., Lowndes, C. M., & Shah, K. V. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.06.015 · Cited by 535
TLR7 Ligands Induce Higher IFN-α Production in Females
Berghöfer, B., Frommer, T., Haley, G., Fink, L., Bein, G., & Hackstein, H. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.4.2088 · Cited by 480
Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential
Stanley, M. A. (2002) · Clinical and Experimental Dermatology · doi:10.1046/j.1365-2230.2002.01151.x · Cited by 377
Metadata
- Authors
- Edwards, L.
- Venue
- Archives of Dermatology
- Publisher
- American Medical Association (AMA)
- Published
- 1998-01-01
- Volume
- 134
- Issue
- 1
- Pages
- 25
- ISSN
- 0003-987X (ISSN-L)
- OpenAlex
- W2095995872
- Cited by
- 559
- References
- 9
- FWCI
- 43.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Self-administered Topical 5% Imiquimod Cream for External Anogenital Warts. https://app.cochat.ai/papers/10.1001/archderm.134.1.25
- The paper
- Edwards, L. (1998). Self-administered Topical 5% Imiquimod Cream for External Anogenital Warts. Archives of Dermatology. https://doi.org/10.1001/archderm.134.1.25
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.